{
    "response": "**Overall Treatment Decision:** Yes\u2014initiate\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Typical unilateral optic neuritis pattern with left RAPD and reduced acuity Early high-dose steroids hasten visual recovery No systemic red flags for infection or sepsis MRI will be arranged urgently to exclude compression; benefits outweigh risks\n\n*   **Treatment:** Proton pump inhibitor for gastroprotection\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Concomitant high-dose corticosteroid therapy Reduces risk of steroid-induced gastritis/ulcer\n\n*   **Treatment:** Oral prednisolone taper after IV pulse\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Initiate only after IV methylprednisolone course Avoid oral steroid monotherapy which increases relapse risk in demyelinating optic neuritis\n\n*   **Treatment:** Therapeutic plasma exchange (5\u20137 exchanges)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve for severe vision loss or failure to improve within 3\u20137 days of IV steroids Particularly effective in NMOSD/MOGAD\n\n*   **Treatment:** Disease-modifying therapy for multiple sclerosis\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start only if MRI/CSF confirm MS Choice depends on risk profile and patient preference\n\n*   **Treatment:** Targeted therapy for NMOSD (e.g., rituximab or satralizumab)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Initiate only if AQP4-IgG positive or diagnostic criteria met Prevents relapses causing permanent vision loss\n\n*   **Treatment:** Pathogen-directed antimicrobial therapy if infectious optic neuritis confirmed\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Avoid steroids alone in untreated infection Tailor to organism such as IV penicillin for syphilis or anti-tuberculous therapy for TB\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Typical unilateral optic neuritis pattern with left RAPD and reduced acuity\", \"Early high-dose steroids hasten visual recovery\", \"No systemic red flags for infection or sepsis\", \"MRI will be arranged urgently to exclude compression; benefits outweigh risks\"]}, {\"treatment\": \"Proton pump inhibitor for gastroprotection\", \"timing\": \"Start Now\", \"reasons\": [\"Concomitant high-dose corticosteroid therapy\", \"Reduces risk of steroid-induced gastritis/ulcer\"]}, {\"treatment\": \"Oral prednisolone taper after IV pulse\", \"timing\": \"Delay\", \"reasons\": [\"Initiate only after IV methylprednisolone course\", \"Avoid oral steroid monotherapy which increases relapse risk in demyelinating optic neuritis\"]}, {\"treatment\": \"Therapeutic plasma exchange (5\\u20137 exchanges)\", \"timing\": \"Delay\", \"reasons\": [\"Reserve for severe vision loss or failure to improve within 3\\u20137 days of IV steroids\", \"Particularly effective in NMOSD/MOGAD\"]}, {\"treatment\": \"Disease-modifying therapy for multiple sclerosis\", \"timing\": \"Delay\", \"reasons\": [\"Start only if MRI/CSF confirm MS\", \"Choice depends on risk profile and patient preference\"]}, {\"treatment\": \"Targeted therapy for NMOSD (e.g., rituximab or satralizumab)\", \"timing\": \"Delay\", \"reasons\": [\"Initiate only if AQP4-IgG positive or diagnostic criteria met\", \"Prevents relapses causing permanent vision loss\"]}, {\"treatment\": \"Pathogen-directed antimicrobial therapy if infectious optic neuritis confirmed\", \"timing\": \"Delay\", \"reasons\": [\"Avoid steroids alone in untreated infection\", \"Tailor to organism such as IV penicillin for syphilis or anti-tuberculous therapy for TB\"]}]"
}